首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Jian-Pi-Yi-Shen Regulates EPO and Iron Recycling Protein Expressions in Anemic Rats with Chronic Kidney Disease: Accumulation of Hypoxia Inducible Factor-2α via ERK Signaling
【24h】

Jian-Pi-Yi-Shen Regulates EPO and Iron Recycling Protein Expressions in Anemic Rats with Chronic Kidney Disease: Accumulation of Hypoxia Inducible Factor-2α via ERK Signaling

机译:建 - 益申患慢性肾病的贫血大鼠EPO和铁回收蛋白表达:通过ERK信号传导缺氧诱导因子-2α积累

获取原文
           

摘要

Jian-Pi-Yi-Shen (JPYS), the traditional Chinese medicine (TCM) decoction, has been commonly used to treat chronic kidney disease (CKD) and its complications such as anemia. JPYS has been previously found to induce erythropoietin (EPO) production in HEK293T cells and CKD rats. However, the mechanism of JPYS in treating anemia of CKD rats has remained largely unknown. Here, we further extend our effort to investigate the translational control of hypoxia inducible factor- (HIF-) α protein via ERK signaling and the effect on iron recycling-related protein expression by JPYS, thus revealing the mechanism of JPYS in correcting anemia in CKD. Experimental CKD rats with anemia were induced by 5/6 nephrectomy. Rats were administrated orally with high dose (6.0?g/kg/d) and low dose (1.5?g/kg/d) of JPYS for 90 days. Serum hepcidin level was determined to evaluate iron homeostasis. The protein expressions of HIF-2α, erythropoietin (EPO), ferritin, and ferroportin (FPN) and the phosphorylation level of extracellular signal-regulated kinase 1/2 (ERK1/2) were detected by Western blot. The results showed that JPYS treatment significantly ameliorated kidney function by reducing increased levels of blood urea nitrogen (BUN), serum creatinine (Scr), and urine protein (UPRO). Periodic acid-Schiff (PAS) and Masson staining observation showed that the renal pathological damage was restored in JPYS-treated CKD rats. In parallel, JPYS markedly improved CKD anemia through upregulation of red blood cell (RBC), hemoglobin (HGB), and hematocrit (HCT). JPYS stimulated EPO and HIF-2α protein expressions in both the kidney and liver of CKD rats. Furthermore, JPYS induced the phosphorylation of ERK1/2 protein. In addition, JPYS regulated protein expression of ferritin and FPN in both the liver and spleen of CKD rats and the serum level of hepcidin. In conclusion, JPYS induces the expression of EPO through ERK-mediated HIF-2α protein accumulation and regulates systemic iron recycling, supporting its role in promoting erythropoiesis and improvement of anemia in CKD.
机译:中医(JPYS),中药(TCM)汤,常常用于治疗慢性肾病(CKD)及其贫血等并发症。以前发现JPYS在HEK293T细胞和CKD大鼠中诱导促红细胞生成素(EPO)生产。然而,JPYS治疗CKD大鼠贫血中的机制仍然很大程度上。在这里,我们进一步努力通过ERK信号传导来研究缺氧诱导因子 - (HIF-)α蛋白的翻译控制和JPYS对铁回收相关蛋白表达的影响,从而揭示了JPYS在校正CKD中贫血的机制。使用5/6肾切除术诱导患有贫血的实验性CKD大鼠。大鼠以高剂量(6.0·G / kg / d)口服,低剂量(1.5·g / kg / d),jpys为90天。确定血清肝素水平评估铁稳态。通过蛋白质印迹检测HIF-2α,促红细胞生成素(EPO),铁蛋白(EPO),铁蛋白和脱霉素(FPN)和细胞外信号调节激酶1/2(ERK1 / 2)的磷酸化水平的蛋白质表达。结果表明,JPYS治疗通过降低血尿尿素氮(BUN),血清肌酐(SCR)和尿蛋白(乌普)的增加而显着改善肾功能。定期酸 - 席夫(PAS)和Masson染色观察表明,在JPYS治疗的CKD大鼠中恢复了肾病病理损伤。并行地,JPYS通过对红细胞(RBC),血红蛋白(HGB)和血细胞比容(HCT)的上调显着改善CKD贫血。 JPYS在CKD大鼠的肾脏和肝脏中刺激了EPO和HIF-2α蛋白表达。此外,JPYS诱导ERK1 / 2蛋白的磷酸化。此外,JPYS在CKD大鼠肝脏和脾脏和血清肝素水平的肝脏和脾脏中的铁蛋白和FPN的调节蛋白表达。总之,JPYS通过ERK介导的HIF-2α蛋白质积累诱导EPO的表达,并调节全身铁回收,支持其在促进促进促进促红细胞的作用和CKD中贫血的改善。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号